Lumos Pharma, Inc.
LUMO · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $14 | $17 | $23 | $35 |
| Short-Term Investments | $0 | $0 | $0 | $1 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $4 | $4 | $4 |
| Total Curr. Assets | $17 | $21 | $28 | $40 |
| Property Plant & Equip (Net) | $0 | $0 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $17 | $21 | $28 | $41 |
| Liabilities | – | – | – | – |
| Payables | $1 | $0 | $1 | $1 |
| Short-Term Debt | $0 | $1 | $0 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $5 | $4 | $4 | $6 |
| Total Curr. Liab. | $7 | $5 | $4 | $7 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $6 | $6 | $6 | $6 |
| Total NC Liab. | $6 | $6 | $6 | $6 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $1 | $1 |
| Total Liabilities | $13 | $11 | $11 | $13 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$187 | -$180 | -$172 | -$162 |
| AOCI | $0 | -$0 | $0 | -$0 |
| Other Equity | $192 | $190 | $189 | $189 |
| Total Equity | $5 | $10 | $17 | $27 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $17 | $21 | $28 | $41 |
| Net Debt | -$13 | -$16 | -$23 | -$34 |